ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.210,48
0,58%
S&P 500
5.187,70
0,13%
US Dollar vs BRL
5,075
0,00%
Bitcoin
62.275,88
-0,09%
Brent Oil
81,885
-1,18%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ligand Pharmaceuticals Incorporated (LGND)

  7. Ligand Pharmaceuticals Incorporated (LGND) Notícias

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LGND
DataHoraFonteTítuloCódigoCompanhia
07/03/202415:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/03/202420:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202418:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202418:49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
27/02/202409:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202408:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202417:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/01/202421:30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202419:40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/12/202310:20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
28/11/202311:01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202323:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202319:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/11/202311:00GlobeNewswire Inc.Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 TrialNASDAQ:LGNDLigand Pharmaceuticals Incorporated
18/10/202309:00GlobeNewswire Inc.Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026NASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/10/202310:00GlobeNewswire Inc.Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
25/09/202319:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/07/202309:45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/06/202310:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual MeetingNASDAQ:LGNDLigand Pharmaceuticals Incorporated
21/06/202310:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/06/202318:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/06/202310:01GlobeNewswire Inc.Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
25/05/202318:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023NASDAQ:LGNDLigand Pharmaceuticals Incorporated
16/05/202314:15Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
08/05/202317:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
26/04/202313:25Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202317:10Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202317:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202317:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
22/02/202318:01Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Apresentando as notícias mais relevantes sobre:NASDAQ:LGND

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
VVEO3
CM Hospitalar ON
BOV
CRFB3
CARREFOUR ON
BOV
ETER3
ETERNIT ON
BOV
AZEV4
AZEVEDO PN
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados